Item 1.01. Entry into a Material Definitive Agreement.
On June 13,
2022, Elys Game Technology, Corp., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the
“Purchase Agreement”) with an institutional investor (the “Investor”) providing for the issuance of (i) 2,625,000
shares (the “Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), (ii) pre-funded
warrants (the “Pre-Funded Warrants”) to purchase up to 541,227 shares of Common Stock (the “Pre-Funded Warrant Shares”)
with an exercise price of $0.0001 per share, which Pre-Funded Warrants are to be issued in lieu of shares of Common Stock to ensure that
the Investor does not exceed certain beneficial ownership limitations, and (iii) warrants (the “Warrants”)
to purchase an aggregate of up to 3,166,227 shares of Common Stock (the “Warrant Shares”) with an exercise price of $0.9475
per share, subject to customary adjustments thereunder. If after the six month anniversary of the issuance date there is no effective
registration statement registering the Warrant Shares for resale, then the Warrants are exercisable on a cashless basis. The Shares, the
Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities.”
Pursuant to the Purchase Agreement, the Investor is purchasing the Securities for an aggregate purchase price of approximately $3 million.
The Company estimates that the net proceeds from the
offering will be approximately $2.6 million after deducting certain fees due to the Placement Agent (as defined below) and the Company’s
estimated transaction expenses. The net proceeds received by the Company will be used for working capital and other general corporate
purposes.
Pursuant to the Purchase
Agreement, an aggregate of 2,625,000 Shares and Pre-Funded Warrants to purchase up to 541,227 shares of Common Stock will be issued to
the Investor in a registered direct offering (the “Registered Offering”) and registered under the Securities Act of 1933,
as amended (the “Securities Act”), pursuant to a prospectus supplement to the Company’s currently effective registration
statement on Form S-3 (File No. 333-256815), which was initially filed with the U.S. Securities and Exchange Commission (the “SEC”)
on June 4, 2021, and was declared effective on June 14, 2021 (the “Shelf Registration Statement”). The Company filed the prospectus supplement for the Registered Offering on June 15, 2022.
Pursuant to the Purchase Agreement, the Company will
issue the Warrants to the Investor in a concurrent private placement pursuant to an exemption from the registration requirements of the
Securities Act provided in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder (the “Private Placement,”
and together with the Registered Offering, the “Offering”).
The Company has agreed to
file a registration statement (the “Registration Statement”) to register the resale of the Warrant Shares within 90 days of
the date of the Purchase Agreement and to use its commercially reasonable efforts to obtain effectiveness of the Registration Statement
within 180 days following the closing of the Offering.
On June 10,
2022, the Company entered into an engagement letter (the “Engagement Letter”), with H.C. Wainwright & Co., LLC (the “Placement
Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company, on a reasonable
best efforts basis, in connection with the Offering. The Company has agreed to pay the Placement Agent an aggregate cash fee equal to
6.0% of the gross proceeds received in the Offering. The Company also agreed to pay the Placement Agent $50,000 for fees and expenses
of legal counsel and up to $15,950 for clearing fees.
The Company expects the offering to close on or about
June 15, 2022, subject to the satisfaction of customary closing conditions in the Purchase Agreement. The Purchase Agreement contains
customary representations, warranties and agreements of the Company and the Investor. The Investor has previously invested in securities
of the Company or otherwise had pre-existing relationships with the Placement Agent and/or the Company; the Company did not engage in
general solicitation or advertising with regard to the issuance and sale of the Securities. The Investor represented to the Company that
it is an “accredited investor” and purchased the Securities for investment purposes and not with a view to distribution.
Certain Terms of the Pre-Funded Warrants and the
Warrants
Each Pre-Funded Warrant is
exercisable for one share of Common Stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable
and may be exercised at any time after their original issuance until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded
Warrants are being offered in lieu of shares of Common Stock to the Investor because the purchase of shares of Common Stock in the Registered
Offering would otherwise result in said Investor, together with its affiliates and certain related parties, beneficially owning more than
4.99% (or, at the election of the Investor, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation
of the Registered Offering.
Each Warrant is exercisable
for one share of Common Stock at an exercise price of $0.9475 per share. The Warrants have a term
of five years and six months from the date of issuance, are exercisable six months from the date of issuance and have an exercise price
of $0.9475 per share, subject to customary adjustments thereunder.
A holder (together with its
affiliates) of the Pre-Funded Warrant or Warrant may not exercise any portion of the Common Stock underlying the Pre-Funded Warrant or
Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%)
of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with
the terms of the Pre-Funded Warrant or Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to
the Company upon exercise of a Pre-Funded Warrant or Warrant in payment of the aggregate exercise price, the holder may elect instead
to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula
set forth in Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at
the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares
of Common Stock to the Warrant holder.
In addition, in certain circumstances,
upon a Fundamental Transaction (as defined in the Pre-Funded Warrants and Warrants), the holders of the Pre-Funded Warrants and Warrants
will have the right to receive as alternative consideration, for each share of Common Stock that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring
corporation of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such
transaction by a holder of the number of shares of Common Stock for which the Pre-Funded Warrants or Warrants are exercisable immediately
prior to such event. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the Warrants have the right
to require the Company or a successor entity to redeem the Warrants for an amount of consideration equal to the Black Scholes Value (as
defined in the Warrants) of the remaining unexercised portion of the Warrants concurrently with or within thirty (30) days following the
consummation of a Fundamental Transaction. In the event of a Fundamental Transaction, the holders of the Warrants will only be entitled
to receive from the Company or its successor entity, as of the date of consummation of such Fundamental Transaction the same type or form
of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrant, that is being offered
and paid to the holders of the Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form
of cash, stock or any combination of cash and stock, or whether the holders of Common Stock are given the choice to receive alternative
forms of consideration in connection with the Fundamental Transaction.
The foregoing description of the Pre-Funded Warrants,
the Warrants, and the Purchase Agreement are qualified in their entirety by reference to the full text of the form of the Pre-Funded Warrant,
the form of the Warrant, and the form of the Purchase Agreement, the forms of which are attached as Exhibits 4.1, 4.2, and 10.1, respectively,
to this Current Report on Form 8-K, and which are incorporated herein in their entirety by reference. The Company is also filing the opinion
of its counsel, Blank Rome LLP, relating to the legality of the issuance and sale of the Shares, the Pre-Funded Warrants and the Pre-Funded
Warrant Shares as Exhibit 5.1 hereto. Exhibit 5.1 is incorporated herein by reference and into the Shelf Registration Statement.